Sickle cell disease, alpha thalassemia, and beta thalassemia are the most common hemoglobinopathies. In terms of value, the global hemoglobinopathy market is estimated to grow at a CAGR of 8.3% over the forecast period, reaching a market valuation of US$ 788.2 Mn by the end of 2027.
The global Hemoglobinopathy Market is anticipated to be worth USD 15.7 billion. From 2019 to 2027, it is predicted to grow at a CAGR of 10.8%. Over the forecast period, rising awareness of hemoglobinopathies and government attempts to diagnose the disorders at an early stage are expected to drive market growth. Furthermore, rising R&D spending, a promising drug pipeline, and technologically advanced diagnostics platforms are projected to propel the market forward.
Read more @ https://cmilatestinsights.blogspot.com/2022/02/global-hemoglobinopathy-market-europe.html
